All Categories
ENEN
Anti-MMR VHH

Anti-MMR VHH

Home >  Modality  >  Proteins  >  Nano-antibody  >  Anti-MMR VHH

Modality

Anti-MMR/CD206 VHH

There has been interest in the diagnostic imaging of protumoral immune cells, such as tumor-associated macrophages (TAMs) subgroups. Of these, the macrophage mannose receptor (MMR), referred to as CD206-positive TAM, has been discovered, including nanobody, also referred to as single domain Antibody (SdAb), or heavy-chain variable (VHH) technology.

For its high affinity with human and mouse MMRs, the anti-MMR nanobody MMR3.49 was screened. A variety of technological strategies such as 68Ga-NOTA conjugation, 18F-fluorobenzoate (18F-SFB) conjugation, and 99mTc tricarbonyl chemistries was adopted to formulate radiolabeled MMR3.49 for PET and SPECT imaging.

A cross-reactive nanobody tracer (68Ga-NOTA-Anti-MMR VHH2) targeting CD206 was developed for imaging 68Ga-labeled CD206+ macrophages of mice tumors. The tracer is currently in a phase I/IIa clinical trial to assess its safety, biodistribution, dosimetry, and tumor intake in patients with breast and melanoma (NCT04168528), and a phase II trial to test its clinical potential in cardiac sarcoidosis, cardiovascular atherosclerosis and oncological disorders (NCT04758650).

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for VHH
Anti-MMR/CD206 VHH In Development

Anti-MMR VHH

Expression System

Stage

Clinical Trials

68Ga-NOTA-Anti-MMR VHH2

Escherichia coli (E. coli)

phase I/IIa

NCT04168528

phase II

NCT04758650
Reference:

[1] Sharifi J, Khirehgesh MR, Safari F, Akbari B. EGFR and anti-EGFR nanobodies: review and update. J Drug Target. 2021 Apr;29(4):387-402. doi: 10.1080/1061186X.2020.1853756.

Get a Free Quote

Get in touch